Skip to main content
. 2023 May 3;14:1187259. doi: 10.3389/fendo.2023.1187259

Figure 7.

Figure 7

Percentage (mean ± SD) of living, early and late apoptotic alongside dead cells in non-treated control cells (CT) and following 17β-estradiol (E2), P4 (P4), and testosterone (T) for 24h alongside dual treatments for 48h with MPP ERα-blocker + E2 (E/α), PHTPP ERβ-blocker + E2 (E/β), mifepristone PGR-blocker + P4 (P/M), and bicalutamide AR-blocker + testosterone (T/B) in the (A) SW480 male and (B) HT29 female colon cancer cell lines (n = 3 biological replicates/group). Treatment with each receptor blocker was for a total duration of 48h in the co-therapy protocols, whilst E2, P4, or T therapies were incubated for 24h and were initiated in the single and dual treatment groups 24h after adding their corresponding receptor blockers for 24h. (Data were analyzed by one-way ANOVA with Tukey’s HSD post-hoc test; a = P< 0.05 compared with CT; b = P< 0.05 compared with E2 group; c = P< 0.05 compared with E/α group, d = P< 0.05 compared with E/β group; e = P< 0.05 compared with P4 group; f = P< 0.05 compared with P/M group, and g = P< 0.05 compared with T group).